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Purpose: To investigate the compensation of secretory mucins with membranous mucins in mice with goblet cell
deficiency.
Methods: A transgenic mouse model in which conjunctival goblet cells were targeted was generated, and the expression
of mucins was evaluated through the toxicity of diphtheria toxin A driven by a human mucin, MUC5AC, promoter.
Immunohistochemical  staining,  in  situ  hybridization,  electronic  microscopy,  and  quantitative  reverse  transcription
polymerase chain reaction (RT–PCR) were used to characterize their phenotypes.
Results: The external appearance of the ocular surface was normal, and no corneal pathology was found. The quantity of
MUC5AC and the number of conjunctival goblet cells decreased in this mouse as expected. However, the membranous
mucin, MUC4, compensates the decrease of MUC5AC in terms of the results of immunohistochemical staining, in situ
hybridization, electronic microscopy, and quantitative RT–PCR.
Conclusions: The membranous mucin, MUC4, can compensate for the deficiency of the secretory mucin, MUC5AC, in
goblet cell deficient mice. This compensation may explain why the symptoms of mucus threads can be found in some
goblet deficiency diseases, and it may provide an alternative defensive mechanism in goblet cell deficiency.
The tear film is composed of an outer lipid layer and an
inner  aqueous  phase,  which  contains  a  variety  of  mucins
adjacent to the glycocalyx of the apical cells of the epithelium.
Ocular  surface  mucins  adhere  to  the  glycocalyces  of
conjunctival and corneal epithelial cells and enhances the
wettability of the cornea by serving as an interface between
the hydrophobic corneal epithelium and the aqueous tear fluid
[1,2]. Therefore, mucin can stabilize the tear film, provide a
smooth and refractive surface of high optical quality over the
cornea,  lubricate  the  corneal  and  conjunctival  epithelial
surfaces during eye blinking, and prevent desiccation of the
ocular surface through water retention resulting from heavy
O-linked glycosylation. It also serves as a barrier to microbial
invasion  and  shields  conjunctival  and  corneal  cells  from
surface debris and noxious substances [3,4].
Fifteen epithelial mucin genes have been completely or
partially  sequenced.  They  are  MUC1,  MUC2,  MUC3A,
MUC3B,  MUC4,  MUC5AC,  MUC5B,  MUC6-MUC9,
MUC11-MUC13,  and  MUC16  [5-10].  According  to  their
physiologic functions, they can be further classified as gel-
forming mucins (MUC2, MUC5AC, MUC5B, and MUC6),
soluble mucins (MUC7 and MUC9), and membrane-spanning
mucins  (MUC1,  MUC3A,  MUC3B,  MUC4,  MUC12,
MUC13, and MUC16). To date, at least five mucins have been
found in the ocular surface epithelium. Conjunctival goblet
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cells secrete the gel-forming mucins, MUC5AC and MUC2,
whose expression at the ocular surface is limited to the goblet
cells of the conjunctiva [11], whereas the conjunctival and
corneal epithelia produce the membrane-spanning mucins,
MUC1, MUC4, and MUC16 [11,12].
Goblet cell mucin secretion is tightly regulated since both
increases and decreases in mucin in the tear film are associated
with ocular surface diseases. Lemp [13] has divided diseases
of the mucous layer into diseases of mucous overproduction
and deficiency. Diseases of mucous overproduction include
giant  papillary  conjunctivitis,  vernal  conjunctivitis,  atopy,
ocular allergy, mucous fishing syndrome, and early dry eye
syndromes. Diseases of mucous deficiency include anesthetic
cornea  (neurotrophic  keratitis),  herpetic  keratitis,  familial
dysautonomia,  alkali  burns,  radiation  burns,  Stephens-
Johnson syndrome, cicatricial pemphigoid, and late dry eye
syndromes.
Patients  with  vernal  keratoconjunctivitis  have  been
shown by impression cytology to have a significant increase
in the number of goblet cells when compared to the number
of goblet cells in normal control subjects [14]. An increased
expression of Muc5AC mRNA was also noted in murine and
human allergic diseases [15,16]. However, two other studies
of goblet cells in a guinea pig model of allergic conjunctivitis
demonstrated a decrease in conjunctival goblet cells [17,18].
Thus, the relationship between the number of goblet cells and
mucin  gene  expression  in  the  ocular  allergic  response  is
unclear.
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108Patients with Sjögren syndrome have reduced levels of
the gel-forming mucin, MUC5AC, in tears, which correlates
with  a  reduced  number  of  MUC5AC  transcripts  in
conjunctival goblet cells and is responsible for decreasing the
fluid on wet epithelial surfaces [19,20]. Argüeso et al. [20]
showed that some cases of dry eye are secondary to a mucus
deficiency  leading  to  decreased  tear  breakup  time.
Furthermore, the conjunctival goblet cell density is found to
decrease by 86% in keratoconjunctivitis sicca and even more
in extreme types of dry eye such as ocular pemphigoid and
Stevens–Johnson syndrome [21,22]. However, mucus threads
on the ocular surface are often complained by these patients
with the status of their goblet cell deficiency.
Past studies have demonstrated that targeted disruption
of a specific cell lineage can be a useful method for evaluating
its function. In these approaches, a toxin gene driven by a
tissue-specific promoter is used to achieve genetic ablation of
a particular cell lineage. Targeted expression of γ2-crystallin
promoter fused to the diphtheria toxin (DT) A-chain gene
(DT-A)  caused  microphthalmia  in  experimental  transgenic
mice  [23].  Similar  targeted  expression  of  the  elastase  I
promoter fused to DT-A caused aplasia of the pancreas in
transgenic mice [24].
In  this  report,  we  used  a  transgenic  approach  to
selectively ablate conjunctival goblet cells by diphtheria toxin
via  the  expression  of  a  minigene  containing  the  human
MUC5AC promoter [25] and an attenuated diphtheria toxin
A-chain gene [26,27]. This transgenic mouse was used to
study  the  consequences  of  goblet  cell  loss  on  mucin
production  by  examining  the  mucin  changes  in  the
conjunctiva, which might be similar to the mucus-deficient
diseases.
METHODS
Generation of transgenic mouse lines: The 680 bp attenuated
diphtheria toxin A cDNA (Tox176) was removed from the
plasmid, Ktnpr-DTa/BpA (a generous gift from Dr. Winston
Kao), by HindIII digestion. The luciferase reporter cDNA in
plasmids containing the 4,068 bp (extending from −4.0 kb to
+68 bp) human MUC5AC promoter in a PGL3 luciferase
reporter  vector  (Promega,  Madison,WI)  was  excised  by
digestion  with  NotI  and  XhoI  and  was  replaced  with  the
attenuated diphtheria toxin A cDNA (Tox176). The human
MUC5AC  with  attenuated  diphtheria  toxin  A  cDNA  was
separated  from  vector  sequences  by  agarose  gel
electrophoresis, purified by glass bead extraction (Geneclean
II, BIO 101 Inc., Vista, CA), suspended in TE buffer (10 mM
Tris, pH 7.4, 0.2 mM EDTA), sterilized by passage through a
0.22-mm filter (Ultrafree-MC, Millipore, Billerica, MA), and
microinjected into the pronuclei of C57BL/6J fertilized mouse
oocytes  by  the  Transgenic  Core  Facility  at  the  Medical
College  of  National  Taiwan  University  (Taipei,  Taiwan).
Transgenic  founders  were  identified  by  Southern
hybridization of mouse tail DNA digested with HindIII and
BamHI using a 32P labeled diphtheria toxin A (DTA) probe
[25,27-29].  Animal  experiments  were  performed  in
compliance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. Animals were housed in
a room maintained at 23 °C with a fixed 12 h light/dark cycle
(lights on from 6 AM to 6 PM) and given free access to Purina
chow (Purina, St. Louis, MO) and water. On the morning of
the experiment, animals were anesthetized with pentobarbital
sodium  (5  mg  per  100  g  bodyweight  by  intraperitoneal
injection).
The transgenic mice were identified by polymerase chain
reaction (PCR) of mouse tail DNA with a primer pair chosen
from within Tox176 (5′-AAC TTT TCT TCG TAC CAC
GG-3′ and 5′-ACT CAT ACA TCG CAT CTT GG-3′) and
another primer pair for the MUC5AC promoter (5′-GGA AAC
TGG GCT CTA CCC GG-3′ and 5′-CAT TGT GTG GAC
GGC  GGG  GA-3′).  Male  mice  heterozygous  for  the
MUC5AC-Tox176  transgene  were  bred  with  female  mice
heterozygous for the MUC5AC-Tox176 transgene to produce
mice  of  four  separate  genotypes:  those  carrying  both
transgenes, those carrying one of the two, and those carrying
neither  transgene.  The  presence  of  the  transgenes  was
determined by PCR analysis of genomic DNA obtained from
tail biopsy and prepared using the QIAmp tissue isolation kit
(Qiagen,  Valencia,  CA).  Sex-matched  littermate  mice
between the ages of two and four months were used for all
experiments.
Visualization and quantitation of conjunctival goblet cells:
To visualize and quantify the filled conjunctival goblet cells,
a modified conjunctival whole mount technique was used
[30,31].  The  eyes  were  enucleated,  and  whole  mounts  of
inferior conjunctiva were dissected and fixed overnight in 4%
paraformaldehyde. These tissues were then rinsed three times
(10 min per rinse) in phosphate buffer saline (PBS; 75.2 g
K2HPO4, 13.2 g NaH2PO4·H2O, and 72 g NaCl dissolved in 1
liter of distilled water). The specimens were treated with 3%
glacial acetic acid for 3 min. They were then incubated with
Alcian blue (AB, pH 2.5; Muto Chemicals, Tokyo, Japan) for
40 min and with 0.5% periodic acid solution (Fisher Scientific,
Pittsburgh, PA) for 5 min. The tissues were then flat-mounted
on a glass slide in Vectashield mounting medium (Vector
Laboratories, Burlingame, CA).
Images were imported into image management software
(Photoshop,  version  5.0;  Adobe,  San  Jose,  CA),  and
measurement of the entire epithelial area was achieved by
tracing the area with the program’s “lasso” tool. The total data
area,  measured  in  pixels,  is  acquired  through  the
“image:histogram”  command  in  the  program.  Two
independent counts are recorded for goblet cells. Goblet cells
per unit area of pixels were adjusted to real unit area or cells
per square millimeter of real epithelial area based on 28.346
pixels/cm  in  the  software  and  a  calibration  factor  of
1  mm=4096  pixels  at  40X  magnification  on  the  confocal
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109microscope. Data were recorded as goblet cells per square
millimeter, and the results were analyzed on the computer
with  ANOVA  (StatView  software,  version  5.0;  Abacus
Concepts, Berkeley, CA).
Immunohistochemical  staining:  A  detailed  morphologic
analysis  of  hematoxylin-eosin  stained,  4  μm  thick  slides
obtained  from  formalin-fixed,  paraffin-embedded  tissue
blocks was performed. Representative sections were stained
with  periodic  acid–Schiff  (PAS),  Alcian  blue,  and
mucicarmine. For all mucin detections, antigen retrieval was
performed by microwaving rehydrated sections in 10 mM
citric acid (pH 6.0) four times for 5 min each with 1 min
between each heating. Monoclonal antibody against MUC1,
MUC2,  MUC4,  MUC5AC,  anti-phospho-p38-Mitogen-
Activated Protein Kinase (p38MAPK), Activating Protein 2
(AP2), anti-phospho-Extracellular Signal-Regulated Kinase
(ERK), and cytokeratin-7 (Santa Cruz Biotechnology, Santa
Cruz, CA) was applied at a 1:40 dilution at 4 °C overnight.
Histochem-Plus kits (Zymed, S. San Francisco, CA) were
used to detect bound primary antibody.
Electron  microscopy:  Samples  were  fixed  in  2.7%
glutaraldehyde  and  0.8%  paraformaldehyde  in  0.1  M
cacodylate buffer (pH 7.4) for 2 h at room temperature. They
were rinsed in distilled water and post-fixed in 2% osmium
tetroxide for 1 h, dehydrated through graded alcohols to 100%
ethanol, and embedded in Eponate resin (Polysciences Inc.,
Warrington, PA). Seventy nanometer sections were cut and
stained with 10% uranyl acetate in 50% ethanol and Reynolds
lead citrate (microwave method). A Philips Bioscan Techni
10 (Philips, Eindhoven, Netherlands) was used at 80 kV for
photography.
Apoptosis  detection  by  Terminal  Deoxynucleotidyl
Transferase  Biotin-dUTP  Nick  End  Labeling  (TUNEL)
staining: Four micrometer thick slides were obtained from
cold, paraformaldehyde fixed embedded tissue for 6 h and
dehydrated in a graded ethanol series (50%, 70%, 85%, 95%,
and 100%) followed by 20 min in acetone at −20 °C. The tissue
section slides were further permeabilized by incubation in
PBS with 0.5% Triton X-100 and 0.1% sodium citrate for 15
min and in a 20 μg/ml proteinase K (Invitrogen, Carlsbad, CA)
for  10  min.  The  samples  were  refixed  with  4%
paraformaldehyde  before  incubation  with  terminal
deoxynucleotidyl transferase (TdT) solution according to the
manufacturer’s instructions (in situ cell death detection kit;
Hoffmann-La Roche Co. Ltd., Basel, Switzerland).
Real-time reverse transcription polymerase chain reaction to
determine  relative  MUC1,  MUC2,  MUC5AC,  and  MUC4
expression: Mouse conjunctivas were snap frozen in liquid
nitrogen,  and  total  RNA  was  isolated  by  a  single-step
extraction  technique  with  reagent  (TRIzol;  Gibco-Life
Technologies, Grand Island, NY). The first strand of cDNA
was  synthesized  from  1  µg  of  DNase-treated  RNA  with
random primers using reverse transcriptase (SuperScript II;
Gibco-Life Technologies) followed by RNase H treatment
(Invitrogen, Carlsbad, CA). Real-time reverse transcription
(RT)–PCR was performed using a sequence detection system
(TaqMan  PCR  GeneAmp  5700;  PE  Applied  Biosystems,
Foster City, CA) essentially as previously described [32,33].
To  normalize  MUC1,MUC2,MUC4,  and  MUC5AC
expression relative to cDNA, we used primers and a TaqMan
probe  corresponding  to  β-actin.  The  MUC5AC-,  MUC4-,
MUC1-, MUC2-, and β-actin-specific primers provided in the
public  domain  by  the  National  Center  for  Biotechnology
(NCBI) [34] are shown in Table 1.
For relative quantitation as performed in this study, a
comparative threshold (CT) method normalizes the amount of
target  compared  with  an  internal  standard  control—for
example, a suitable housekeeping gene. The relative amount
of  a  target  gene  in  different  samples  is  determined  and
compared with the amount in the naïve control specimens
(calibrator specimen). The internal standard control gene is
amplified using rodent β-actin. To verify the validity of using
β-actin as the internal calibration standard, the efficiencies of
the  MUC5AC,  MUC4,  and  β-actin  amplifications  were
compared and found to be equivalent. The identities of the
MUC5AC  and  MUC4  PCR  products  were  verified  by
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110sequencing performed by the DNA Sequencing Core Facility
of the National Taiwan University Hospital.
Each  PCR  reaction  contained  equivalent  amounts  of
cDNA.  Assays  were  performed  in  triplicate  using  a  kit
according to the manufacturer’s recommendations (TaqMan
PCR Reagent Kit; PE Biosystems). Relative quantitation of
the amounts of MUC1, MUC5AC, and MUC4 mRNAs at 0 h,
6 h, 24 h, and 48 h after final antigen challenge was determined
as previously described [32]. The results were analyzed using
the unpaired t-test.
In situ hybridization techniques for MUC4 and MUC5AC: In
situ hybridization was performed on sections from mouse
tissue  using  DIG-labeled  antisense  oligonucleotide  probes
corresponding to the tandem repeat regions of MUC4 and
MUC5AC. The sequences used for the DIG-labeled 5′ end of
MUC1  antisense,  MUC2  antisense,  MUC4  antisense,  and
MUC5AC  antisense  oligonucleotide  probes  are  shown  in
Table 2. Techniques used are as previously described [35].
Briefly, paraffin sections were deparaffinized and treated with
proteinase K. The samples were acetylated and hybridized
overnight  with  10  pmole  DIG-labeled  probes.  To  remove
nonspecific binding, slides were subjected to a stringent wash
with 0.5X SSC at 65 °C and treated with 20 μg/ml RNase
(Sigma, St. Louis, MO) at room temperature for 1 h followed
by washing with 0.2X SSC at 65 °C. The hybridization signals
were visualized with anti-DIG antibody alkaline phosphatase
conjugates  using  procedures  recommended  by  the
manufacturer (Hoffmann-La Roche Co. Ltd.). Finally, the
sections  were  counterstained  with  0.5%  neutral  red  and
mounted. Images were obtained using an AxioCam digital
camera (Carl Zeiss Co., Oberkochen, Germany) on Stemi
SV11 Apo (Zeiss) dissection microscope. As a control, in situ
hybridization using a sense oligonucleotide probe for MUC4
and for MUC5AC (Table 2) was performed on all tissues.
RESULTS
Goblet  cell–specific  reporter  gene  expression  by  human
MU5AC promoter in transgenic mice: A construct comprising
TABLE 2. SEQUENCES USED FOR THE DIG-LABELED 5′ END OF OLIGONUCLEOTIDE PROBES.
Gene Sequence
MUC5AC antisense oligonucleotide, 5′-GGTTGTAGAGATGGTGCTGGTCTTTCCTGTATTGGGTGAGCTGGTTTG-3′
sense oligonucleotide probe, 5′-CAAACCAGCTCACCCAATACAGGAAAGACCAGCACCATCTCTACAACC-3′
MUC4 antisense oligonucleotide, 5′-TGTAGAACCTTGAGTCCTTACTGCTGTTGTGTGTCCTGTG-3′
sense oligonucleotide probe, 5′-CACAGGACACACAACAGCAGTAAGGACTCAAGGTTCTACA-3′
MUC1 antisense oligonucleotide, 5′-ACTGGTAGAGTCTTCAGGAGCTCTGGTGGCTGGAGAAGAGGTGCTACT-3′
MUC2 antisense oligonucleotide, 5′-GGAGGGTGTTGGTGTTGGTGTTGAGGGTGTAGGAGTTGAGGGAGTAGA-3′
Figure  1.  Goblet  cell–specific
expression  of  EGFP  by  human
MUC5AC promoter in transgenic mice.
Transgenic mice were produced by an
injection of a construct composed of the
4.0 kb of the 5′ end of human MUC5AC
promoter  that  was  ligated  to  EGFP.
Tissues were fixed and observed under
fluorescent  microscopy  to  locate  the
expression  of  EGFP  as  detailed  in
Methods.  A:  Differential  interference
contrast  (DIC)  picture  of  transgenic
mouse conjunctiva. B: Frozen section of
conjunctival  tissue  with  EGFP
expression  in  the  same  section.  C:
Merged picture of A and B.
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1114.0 kb of the human MUC5AC peomoter ligated to 5’ end of
the reporter Enhanced Green Fluorescent Protein (EGFP) was
used to establish transgenic murine lines. As demonstrated in
Figure 1, the reporter EGFP, which has been driven by the
human MUC5AC promoter, was expressed in conjunctival
goblet cells. The same pattern of expression was observed in
each of four lines derived from individual founder mice. Of
note,  EGFP  was  not  detected  in  other  ocular  tissues,
confirming  both  the  cell-  and  tissue-specificity  of  human
MUC5AC promoter–driven gene expression.
Characterization of human MUC5AC-DTA transgenic mice:
A  4.0  kb  human  MUC5AC  promoter  was  used  to  create
transgenic  mice  that  overexpressed  a  680  bp  attenuated
diphtheria toxin A cDNA (Tox176). Nine transgenic founders
(F0) were generated and identified by PCR and Southern blot
analysis. They were all established as stable transgenic mouse
lines  by  breeding  with  C57BL/6J  mice  (Figure  2).  The
integrity of the transgene DNA and its copy number were
determined by Southern blot analysis with HindIII, which
makes a single cut at the 345th bp of the minigene. A 4.7 kb
genomic DNA fragment was hybridized to the  32P-labeled
cDNA of diphtheria toxin. The copy number of the transgene
varied from 1 to 10 among the nine founder lines. Transgenic
mouse lines, C1, C2, C3, C4, and C5, had approximately one
copy of the minigene inserted into the genome of transgenic
mouse line. C6, C7, C8, and C9 had more than one copy of
the minigene inserted in tandem, and overexposure of the
Southern blot hybridization did not yield evidence to support
multiple  insertion  sites  in  the  genome.  Those  mice  with
multiple copies of the minigene were not used for further
analysis because they were infertile. This phenomenon may
be a toxic effect to the germ cells due to the ectopically
Figure 2. Southern blot analysis to determine the copy number of the human MUC5AC-DTA transgene in human MUC5AC-DTA(+/−)
transgenic mice. Arrow at the left indicates the 4.7 kb MUC5AC-DTA transgene construct in the control and the fragments liberated from the
genomic DNA of transgenic mice by HindIII digestion. The copy number of the transgene varied from 1 to 10 among the nine founder lines.
Transgenic mouse lines, C1, C2, C3, C4, and C5, had approximately one copy of the minigene inserted into the genome of transgenic mouse
line. C6, C7, C8, and C9 had more than one copy of the minigene inserted in tandem.
Figure  3.  Phenotypes  of  human
MUC5AC-DTA transgenic mice. A: The
transgenic mice are smaller than normal
mice and have prominent hair loss. B:
The bodyweights of transgenic mice are
less than those of normal mice at the age
of  three  months.  C:  The  left  image
shows the normal external eye of the
transgenic mouse and the right image
shows  the  fluorescein  staining  of  the
cornea. There is no fluorescein staining
in  the  cornea  and  the  conjunctiva  of
transgenic mice.
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112expressed transgene. Those mice with multiple copies of the
minigene might have a more toxic effect on the germ cells
than those with one copy. The mice with one copy of the
minigene were successfully obtained and then bred. However,
these mice also lose their fertility gradually after four to five
generations due to the toxic effect to germ cells.
The transgenic mice are smaller than normal mice, and
hair loss is prominent in transgenic mice (Figure 3A). The
bodyweights of transgenic mice are less than those of normal
mice at the age of three months (n=5, Figure 3B). However
the external eye, which is the cornea and conjunctiva, looks
normal, and there is no fluorescein staining after application
of fluorescein dye in the conjunctival sac (Figure 3C). To
determine the density of goblet cells in conjunctiva, whole
mount Alcian blue staining was used to count the number of
goblet cells in the mouse conjunctival epithelial sheet. The
density of goblets cells in transgenic mice was less than that
of control mice (n=5, Figure 4A).
To  examine  the  morphological  changes  in  human
MUC5AC-DTA  transgenic  mice,  the  conjunctiva  of
transgenic mice and non-transgenic littermates were subjected
to histological examination. In Alcian blue and mucicarmine
Figure  4.  Expression  of  mucins  in
conjunctivas  of  normal  mouse  and
transgenic mouse. A: Visualization and
quantitation of conjunctival goblet cells
are shown. Whole mount Alcian blue
staining was used to count the number
of goblet cells in the mouse conjunctival
epithelial sheets. The density of goblets
cells in transgenic mice was less than
that of control mice. B: The conjunctiva
of  MUC5AC-DTA  transgenic  mouse
(left  column)  and  control  littermate
(right column) were subjected to mucin
histological  examination  (100X).  In
Alcian blue staining (middle panel) and
mucicarmine staining (lower panel), the
expression  of  mucin  decreased  in
transgenic mouse.
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113stainings, the expression of mucin decreased in transgenic
mice (Figure 4B). In immunohistochemical stainings, both
transgenic mice and control mice expressed normal patterns
of MUC1. However, the expression of MUC5AC and MUC2
decreased  in  transgenic  mice.  The  intensity  of
Figure 5. Immunohistochemical staining against different mucins in conjunctivas. In immunohistochemical stainings (100X), both transgenic
mice and control mice expressed the normal patterns of Muc1 (A and B). The expression of MUC5AC (G,H) and MUC2 (C,D) decreased in
transgenic mice. The intensity of MUC4 immunostaining increased in transgenic mice (E,F).
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114immunostaining  of  MUC4  increased  in  transgenic  mice
(Figure 5).
In situ hybridization showed that there was also decreased
expression of MUC5AC mRNA and increased expression of
MUC4 mRNA (Figure 6). We also used quantitative RT–PCR
to measure the mRNA of mucin expression in transgenic mice.
We  found  that  the  expression  of  MUC2  and  MUC5AC
decreased in transgenic mice. However, MUC4 expression
increased in transgenic mice (Figure 7).
An  electron  microscopy  study  revealed  that  electron
dense materials in the secretary granules, which contain the
secretory mucins in goblet cells, decreased in transgenic mice
(Figure  8).  Finally,  TUNEL  staining  was  used  to  study
apoptotic  cells  in  conjunctival  epithelium.  We  found  that
TUNEL-positive  cells  can  be  found  in  the  conjunctival
epithelium, especially in goblet cells (Figure 9).
A positive staining of ant-phosphop38MAPK could be
detected  in  the  conjunctival  goblet  cells  and  conjunctival
epithelial cells of transgenic mice but not in the control mice
(Figure 10A,B). Similar staining patterns could be observed
for  anti-phospho-ERK  and  AP2  in  conjunctivas  between
transgenic mice and control mice (Figure 10C-F).
DISCUSSION
In the current study, we used a transgenic mouse model to
mimic goblet cell deficient conjunctivitis as mentioned above.
Our results confirmed the hypothesis that MUC4 mucin can
compensate for the decrease of secreted MUC5AC mucin in
diseases of goblet cell deficiency as reported by Dogru et al.
Figure 6. In situ hybridization of MUC4
and  MUC5AC  mRNA.  MUC5AC
mRNA  decreased  (D)  and  MUC4
mRNA (B) increased expression in the
conjunctiva  of  transgenic  mice
compared  with  those  of  their  control
littermates  (A  and  C).  Magnification,
200X.
Figure 7. Expression of different mucin
mRNA  in  conjunctivas.  Quantitative
RT–PCR was used to measure mucin
mRNA.  The  expression  of  MUC2
mRNA and MUC5AC mRNA decreased
while  the  expression  of  MUC4
increased  in  the  conjunctivas  of
transgenic mice compared with those of
their control littermates.
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115[36]. Overexpression of these mucins may also explain the
excessive mucus discharge observed in eyes with allergy or
early dry eye diseases. In allergic diseases, it is possible that
the initial response of the atopic ocular surface epithelium to
inflammation  in  regard  to  mucin  secretion  may  be  a
downregulation  of  epithelial  mucins  relative  to  healthy
control  eyes  [36].  The  goblet  cell  densities  and  mRNA
expressions  of  MUC5AC  showed  a  dramatic  reduction  in
atopic patients with a severe epithelial disease, especially in
patients with corneal ulcers, relative to patients without any
epithelial  disease  and  healthy  control  subjects  [36].  They
suggested that based on the analysis of MUC1,MUC2, and
MUC4 mRNAs, the ocular surface epithelial cells might be
secreting other mucins to compensate for the decrease of
MUC5AC and to protect the ocular surface [37]. Our results
also demonstrated the same trend of mucin compensation
described by Dogru et al. [36].
There are notable differences between the Dogru et al.
[36] study and ours. First, we used an animal model that lacks
atopic eye diseases as well as a normal morphology of the
cornea and conjunctiva. Thus, there will be some differences
in mucin expression between species. Second, the expression
of MUC1,MUC2, and MUC4 are upregulated in the Dogru et
al. [36] study. In our study, only MUC4 was upregulated. The
differential  expression  of  mucin  genes  in  different  ocular
diseases was also noted in the previous report. For example,
both  the  membrane-spanning  mucin,  asialoglycoprotein
(ASGP),  and  the  gel-forming  mucin,  rMuc5AC,  were
downregulated by vitamin A deficiency in rat ocular surface
epithelium [38]. Danjo et al. [39] reported that MUC4 may be
the source of mucin that compensates for loss of MUC1 in
some strains of MUC1 null mice, which do not have ocular
surface anomalies. The mRNA level of MUC4 in the ocular
surface tissue of the MUC1 null mice was not upregulated
when compared with that of control mice through real-time
PCR, an observation that has also been reported by another
paper that used slot-blot analysis of mRNA of the mammary
gland, salivary gland, lung, stomach, and colon of MUC1 null
mice [40]. The possible cause of these differences is that there
is a high level of expression of the membrane-spanning mucin,
Figure 8. Electron microscopic findings
of  secretory  granule  in  conjunctivas.
Electron-dense  materials  (secretory
mucins)  in  the  secretary  granules
decreased  in  transgenic  mice  (right)
compared  with  those  of  their  control
littermates  (left).  Magnification,
12,000X.
Figure  9.  Apoptotic  cells  in
conjunctivas. TUNEL staining was used
to study apoptotic cells in conjunctival
epithelium  (200X).  There  were
significantly  more  TUNEL-positive
cells in the MUC5AC-DTA mice (right)
compared  with  those  of  their  control
littermates (left).
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116MUC4, in the conjunctiva and cornea of rats and mice [38,
41]. In humans, the level of expression of MUC4 in the central
cornea is much lower [11,42]. It is also possible that these
differences  reflect  the  relatively  high  concentration  and
importance of MUC4 on rodent eyes relative to that of MUC1,
which has a negligible effect on the rodent ocular surface.
Therefore,  in  our  study,  MUC4  is  upregulated  instead  of
MUC1.
Another possible way in which mucin alteration may be
involved in ocular surface diseases relates to changes in mucin
glycosylation  in  our  animal  model  as  previously  reported
[43]. The expression pattern of members of the GalNAc-
transferase family, which are the enzymes responsible for
initiation  of  mucin  O-glycosylation,  is  altered  during  the
keratinization process that leads to severe dry eye in ocular
cicatricial pemphigoid patients [43]. In the early stages of the
disease,  GalNAc-T2  and  -T6  isoenzymes,  normally  not
expressed in the apical cells of the conjunctival epithelium,
are expressed in these cells. There is either a compensatory
upregulation  of  GalNAc-transferases  that  results  in  an
increase in the density of O-glycan residues, an alteration in
O-glycan  structure,  and/or  the  glycosylation  of  additional
proteins synthesized by the cell. As the disease progresses and
the conjunctival epithelium becomes keratinized, GalNAc-T6
and GalNAc-T2 isoenzymes in the apical stratified epithelia
disappear, and the levels of GalNAc-T1, -T3, and -T4 are
dramatically reduced. It is possible that the upregulation of
membrane-spanning  MUC4  seen  in  our  data  might  be  a
compensatory mechanism like that of GalNAc-transferases.
Muc4 was known to interact with erythroblastic leukemia
oncogene homolog 2 (erbB2) to enhance tumorigenesis. This
interaction was associated with the hyperphosphorylation of
Mitogen-Activated  Protein  Kinase  (MAPK)  with  the
overexpression  of  cyclooxygenase-2  [44].  Our  study  also
confirmed that upregulation of MUC4 might be through the
hyperphosphorylation of MAPK in the transgenic mice. In
contrast, other signal transduction pathways such as ERK and
AP2 were not involved in the upregulation of the MUC4
expression.
There have been few studies using transgenic animals to
study the function of goblet cells and the expression of mucin.
Itoh  et  al.  [45]  generated  transgenic  mice  expressing
attenuated DT gene, which was driven by the intestinal trefoil
factor (ITF) promoter to assess the functional role of goblet
cells  in  the  intestine.  The  transgenic  mice  showed  partial
ablation  of  the  goblet  cells,  making  possible  functional
assessment  of  diminished  goblet  cell  populations.
Paradoxically, these mice showed marked protection against
Figure 10. Possible mechanisms of the
phenotypes  of  MUC5AC-DTA.  In
immunohistochemical  stainings
(100X), the expression of anit-phospho-
p38MAPK was detected in conjunctival
goblet cells and conjunctival epithelial
cells  of  transgenic  mice  but  not  in
control  mice  (A,B).  Both  transgenic
mice  and  control  mice  expressed  the
similar  patterns  of  anti-phospho-ERK
(C,D)  and  AP2  (E,F).  The
compensatory overexpression of MUC4
in  MUC5AC-DTA  mice  is  possibly
mediated  through  the  expression  of
p38MAPK.
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117exogenous toxic agents such as dextran sodium sulfate (DSS)
and  acetic  acid  because  ITF  expression  and  goblet  cell
numbers are increased in mITF/DT-A mice. They concluded
that mucosal protection may be determined more by adequate
ITF expression than by goblet cells themselves. In our study,
we found that the number of goblet cells decreased with partial
ablation  by  the  human  MUC5AC  promoter  with  DT-A.
However, as in the results from Itoh et al. [45], we observed
compensatory  mechanisms  for  defense  against  external
stimuli in our mice. The transgene appeared to be more highly
expressed within the conjunctival goblet cells and was not
observed in other cell types. Further, overall tissue specificity
was preserved and aberrant expression was not present in
tissues  that  do  not  normally  express  goblet  cells.  These
findings suggest that the 4.06 kb of the 5′ flanking sequence,
which was used to drive DT-A expression, contains sufficient
regulatory information to confer cell- and tissue-specificity
but may not contain other enhancer elements necessary for
expression.
In conclusion, we found that the membranous mucin,
MUC4, can compensate for the deficiency of the secretory
mucin,  MUC5AC,  in  goblet  cell  deficient  mice.  This
compensation  may  explain  why  the  symptoms  of  mucus
threads can be found in some goblet deficiency diseases, and
it may also provide an alternative defensive mechanism in
goblet cell deficiency.
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